Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

15.83
-0.2700-1.68%
Post-market: 15.43-0.4000-2.53%19:30 EDT
Volume:921.17K
Turnover:14.68M
Market Cap:874.52M
PE:-5.74
High:16.91
Open:16.32
Low:15.33
Close:16.10
52wk High:16.93
52wk Low:5.97
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.45
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:2.15
PE(LYR):-6.54

Loading ...

Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

Dow Jones
·
Jun 29

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of DR. Dean Baker

THOMSON REUTERS
·
Jun 26

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 117,720 in Common Shares

Reuters
·
Jun 26

4D Molecular Therapeutics CEO David Kirn disposes of 114,746 common shares worth $1.2 million

Reuters
·
Jun 24

4D Molecular Therapeutics Stockholders Back Directors and Governance

TIPRANKS
·
Jun 23

4D Molecular Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 23

4D Molecular Therapeutics grants 66,900 RSUs to seven new employees under inducement plan

Reuters
·
Jun 13

4D Molecular Therapeutics CEO David Kirn sells 1,922 shares worth $19,260.06

Reuters
·
Jun 03

4D Molecular Therapeutics to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

4D Molecular Therapeutics grants 141,100 RSUs to 14 new employees

Reuters
·
May 16

Daniel Giraldo Reiterates Buy on 4D Molecular Therapeutics, Citing Strong 4D-150 Progress and Undervalued Upside vs. $29 Price Target

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)

TIPRANKS
·
May 09

4D Molecular Therapeutics Inc - May Offer and Sell up to $400 Mln of Securities in Multiple Offerings - SEC Filing

THOMSON REUTERS
·
May 08

4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retinal gene therapy program

Reuters
·
May 08

4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate

Benzinga Earnings
·
May 08

BRIEF-4D Molecular Therapeutics Q1 Net Income USD -68.76 Million Vs. IBES Estimate USD -62.6 Million

Reuters
·
May 08

4D Molecular Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Reuters
·
May 05

4D Molecular Therapeutics to present at BofA Securities Healthcare Conference

Reuters
·
May 04

4D Molecular Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

4D Molecular Therapeutics grants 67,600 RSUs under 2025 employment inducement plan

Reuters
·
Apr 18